$PTEX veterinary drug play, Aratana Therapeutics (NASDAQ: PETX), which has had three drugs approved so far in 2016, a major accomplishment for any small developmental firm. 2017 will see these compounds hit the market in full force and Aratana will move away from being a non-profitable developmental firm as it begins commercialization efforts. The company has already signed a lucrative distribution deal for its first drug “galliprant” and I would look for similar deals on the other two compounds in the next few quarters which should be a positive for the stock and boost initial sales as well. The stock seems significantly undervalued here with a market capitalization of just under $275 million with plenty of cash on the balance sheet.